Fig. 2

Sankey diagrams for patients receiving regimens of interest by ASCT status (n = 12,095). LoT, line of therapy; ASCT, autologous stem cell transplantation. Sankey diagrams are presented to assess longitudinal treatment sequencing for patients receiving any of the regimens of interest at 1 L: (a) overall, (b) for patients who received ASCT in any LoT, and (c) for patients who did not receive ASCT in any LoT. Treatment sequencing for patients receiving regimens of interest at 1 L differed according to whether the patients did or did not receive ASCT during the follow-up period. Bortezomib plus thalidomide, bortezomib plus cyclophosphamide, or bortezomib monotherapy were received by 99.3% of patients who received ASCT in any LoT (i.e. 2,194 of 2,209 patients); however, these regimens were received by 83.5% of patients who did not receive ASCT (i.e. 4,885 of 5,853 patients). In addition, 100 patients (4.5%) who received ASCT in any LoT died after receiving 1 L, while 2,078 patients (35.5%) who did not receive ASCT in any LoT died after receiving 1 L.